Head to Head Analysis: Harrow (NASDAQ:HROW) and Clene (NASDAQ:CLNN)

Harrow (NASDAQ:HROW) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Harrow and Clene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	7	0	2.60
Clene	1	0	6	0	2.71

Harrow presently has a consensus price target of $66.17, suggesting a potential upside of 117.08%. Clene has a consensus price target of $34.00, suggesting a potential upside of 733.33%. Given Clene’s stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Harrow.

Risk and Volatility

Harrow has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Harrow and Clene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Clene	-20,063.96%	N/A	-137.04%

Valuation and Earnings

This table compares Harrow and Clene”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	4.20	-$5.14 million	($1.00)	-30.48
Clene	$200,000.00	265.00	-$26.17 million	($3.50)	-1.17

Harrow has higher revenue and earnings than Clene. Harrow is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

72.8% of Harrow shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.